A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in over 100 million infections and millions of deaths. Effective vaccines remain the best hope of curtailing SARS-CoV-2 transmission, morbidity, and mortality. The vaccines in current use require cold st...

Descripción completa

Detalles Bibliográficos
Autores principales: Pishesha, Novalia, Harmand, Thibault J., Rothlauf, Paul W., Praest, Patrique, Alexander, Ryan K., van den Doel, Renate, Liebeskind, Mariel J., Vakaki, Maria A., McCaul, Nicholas, Wijne, Charlotte, Verhaar, Elisha, Pinney, William, Heston, Hailey, Bloyet, Louis-Marie, Pontelli, Marjorie Cornejo, Ilagan, Ma. Xenia G., Jan Lebbink, Robert, Buchser, William J., Wiertz, Emmanuel J. H. J., Whelan, Sean P. J., Ploegh, Hidde L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2021
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612213/
https://www.ncbi.nlm.nih.gov/pubmed/34654739
http://dx.doi.org/10.1073/pnas.2116147118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612213/
https://www.ncbi.nlm.nih.gov/pubmed/34654739
http://dx.doi.org/10.1073/pnas.2116147118

Ejemplares similares